The phase I clinical trial of the HSP90 inhibitor (SNX-5422) assessed the safety and efficacy of using SNX-5422 along with carboplatin and paclitaxel in patients with advanced lung cancer [228]. This evidence concerns the gene HSP90AA1 and lung cancer.